Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant decline in short interest in April. As of April 30th, there was short interest totaling 300 shares, a decline of 91.4% from the April 15th total of 3,506 shares. Based on an average daily volume of 223,293 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s stock are sold short.

Bioxytran Stock Performance

Shares of OTCMKTS BIXT traded up $0.00 during mid-day trading on Monday, hitting $0.04. 27,400 shares of the stock traded hands, compared to its average volume of 88,101. Bioxytran has a 52 week low of $0.03 and a 52 week high of $0.17. The company has a market cap of $4.04 million, a price-to-earnings ratio of -1.78 and a beta of 1.95. The stock has a fifty day moving average price of $0.04 and a 200-day moving average price of $0.06.

About Bioxytran

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.